Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
Blocking the immunoinhibitory PD-1:PD-L1 pathway using monoclonal antibodies has led to dramatic clinical responses by reversing tumor immune evasion and provoking robust and durable antitumor responses. Anti-PD-1 antibodies have now been approved for the treatment of melanoma, and are being clinica...
Saved in:
Main Authors: | Aaron Prodeus (Author), Aws Abdul-Wahid (Author), Nicholas W Fischer (Author), Eric H-B Huang (Author), Marzena Cydzik (Author), Jean Gariépy (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival
by: Aaron Prodeus, et al.
Published: (2014) -
Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
Published: (2020) -
Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
by: Yiting Wang, et al.
Published: (2020) -
Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
by: Xiujing He, et al.
Published: (2022) -
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
by: Yiting Wang, et al.
Published: (2018)